An innovative laser treatment for early vocal-cord cancer, developed at Massachusetts General Hospital (MGH), successfully restores patients’ voices without radiotherapy or traditional surgery, which can permanently damage vocal quality. This new option for patients, which has now been used in more than 25 patients, was reported on May 1 at the annual meeting of the American Broncho-Esophagological Association, and the data will soon be published as a supplement to the Annals of Otology, Rhinology, & Laryngology.
“We had previously adapted lasers that target blood vessels to treat precancerous vocal-cord dysplasia and a variety of benign vascular lesions. We have now applied that experience to treat vocal-cord cancer, which is diagnosed in several thousand American patients each year,” says Steven Zeitels, MD, director of the MGH Voice Center.
Zeitels’ team began applying pulsed lasers to the treatment of early vocal-cord cancer more than five years ago. After successfully treating the first eight patients with the pulsed-dye laser, Zeitels’ group switched to the more precise pulsed Potassium-Titanyl-Phosphate (KTP) laser, which is even less likely to damage delicate vocal-cord tissue. The use of specific wavelengths of laser light to target blood vessels was originally applied to the removal of vascular skin lesions like port-wine stains by Rox Anderson, MD, now director of the MGH Wellman Center of Photomedicine. In a close collaboration with Anderson, Zeitels previously developed application of these angiolytic lasers to benign and precancerous vocal-cord lesions.
As Zeitels reported at the ABEA meeting, the first 22 patients receiving pulsed laser treatment for vocal-cord cancer are cancer-free up to 5 years after treatment, without removal of vocal-cord tissue or loss of voice quality. Some have required second or third laser treatments to remove residual disease, but another benefit of the therapy is that it does not rule out future therapeutic options. Zeitels notes that this treatment has become a standard management approach at MGH and should soon spread to other institutions in the US and abroad. He estimates that 90 percent of patients with early vocal-cord cancer would be candidates for pulsed-KTP laser treatment.
“Currently the optimal angiolytic laser for vocal-cord problems, the pulsed-KTP laser is a critical innovation in the instrumentation arsenal of the laryngeal surgeon,” says Zeitels. “It has greatly enhanced the precision by which we can perform many procedures for chronic laryngeal diseases, both in the operating room, accompanied by the surgical microscope, and in the office.” Zeitels is the Eugene B. Casey Professor of Laryngeal Surgery at Harvard Medical School (HMS).
The MGH Voice Center team has created a number of groundbreaking procedures and was the first in the world to treat vocal cords and other structures in the larynx with controlled pulses of the green KTP laser light. Zeitels has been recognized for his 2006 use of pulsed-KTP laser to treat Steven Tyler of the rock band Aerosmith for vocal-cord hemorrhage. With his unique perspective on voice restoration and preservation resulting from years of treating elite singers, Zeitels was called on to work with Julie Andrews after she lost her singing voice due to a failed surgical procedure. He subsequently has collaborated with Miss Andrews to increase awareness of voice problems and spearhead a research project investigating new voice restoration surgical procedures.
The MGH and HMS instituted one of the first academic programs in Laryngology in the United States in 1870. The MGH program was discontinued in the 1920s and was reestablished in 2004 with the philanthropic assistance of the Eugene B. Casey Foundation and the Institute of Laryngology and Voice Restoration (ILVR – website at http://ilvr.org/), a patient-based organization with the mission to further research, clinical care and education in laryngeal and voice disorders. Miss Andrews is the honorary chairwoman of the ILVR, and the organization’s president is John Ward, PhD, a Northwestern University professor who was the first patient to receive the new laser treatment for vocal-cord cancer.
Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of nearly $500 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, transplantation biology and photomedicine. MGH and Brigham and Women’s Hospital are founding members of Partners HealthCare HealthCare System, a Boston-based integrated health care delivery system.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.